Source: Rare tumors. Unidade: FM
Subjects: NEOPLASIA ENDÓCRINA MÚLTIPLA, ESTUDOS RETROSPECTIVOS, METÁSTASE NEOPLÁSICA (DIAGNÓSTICO), PROLIFERAÇÃO CELULAR, ANTINEOPLÁSICOS (USO TERAPÊUTICO), CARCINOMA
ABNT
MUNHOZ, Rodrigo Ramella et al. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, v. 5, n. 3, p. 135-139, 2013Tradução . . Disponível em: https://doi.org/10.4081/rt.2013.e39. Acesso em: 23 maio 2024.APA
Munhoz, R. R., Rego, J. F. de M., Ferrari, A. R. de C., Braghiroli, M. I., Bariani, G. M., Hoff, P. M., et al. (2013). Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare tumors, 5( 3), 135-139. doi:10.4081/rt.2013.e39NLM
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 maio 23 ] Available from: https://doi.org/10.4081/rt.2013.e39Vancouver
Munhoz RR, Rego JF de M, Ferrari AR de C, Braghiroli MI, Bariani GM, Hoff PM, Costa FP, Pfiffer TEF, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas [Internet]. Rare tumors. 2013 ; 5( 3): 135-139.[citado 2024 maio 23 ] Available from: https://doi.org/10.4081/rt.2013.e39